NCT06910072View on ClinicalTrials.gov

Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

April 2, 2025

Primary Completion Date

October 1, 2026

Study Completion Date

October 1, 2028

Conditions
Triple-Negative Breast Cancer (TNBC)Neoadjuvant Therapy
Interventions
DRUG

paclitaxel polymeric micelles + carboplatin + iparomilimab and tuvonralimab

paclitaxel polymeric micelles 300mg/m2, d1 carboplatin AUC=5, d1 iparomilimab and tuvonralimab 5mg/kg, d1 Every 3 weeks (Q3W) is a cycle, a total of 6 cycles.

Trial Locations (1)

100021

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER